These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 16855457

  • 1. Decreased use of clonidine following treatment with atomoxetine in children with ADHD.
    Johnston JA, Ye W, Van Brunt DL, Pohl G, Sumner CR.
    J Clin Psychopharmacol; 2006 Aug; 26(4):389-95. PubMed ID: 16855457
    [Abstract] [Full Text] [Related]

  • 2. Predictors of selecting atomoxetine therapy for children with attention-deficit-hyperactivity disorder.
    Van Brunt DL, Johnston JA, Ye W, Pohl GM, Sun PJ, Sterling KL, Davis ME.
    Pharmacotherapy; 2005 Nov; 25(11):1541-9. PubMed ID: 16232017
    [Abstract] [Full Text] [Related]

  • 3. Pharmacotherapy with atomoxetine for US children and adolescents.
    Bhatara VS, Aparasu RR.
    Ann Clin Psychiatry; 2007 Nov; 19(3):175-80. PubMed ID: 17729019
    [Abstract] [Full Text] [Related]

  • 4. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 5. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A, LYCY Study Group.
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
    Christensen L, Sasané R, Hodgkins P, Harley C, Tetali S.
    Curr Med Res Opin; 2010 Apr; 26(4):977-89. PubMed ID: 20178404
    [Abstract] [Full Text] [Related]

  • 7. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
    Adler LA, Sutton VK, Moore RJ, Dietrich AP, Reimherr FW, Sangal RB, Saylor KE, Secnik K, Kelsey DK, Allen AJ.
    J Clin Psychopharmacol; 2006 Dec; 26(6):648-52. PubMed ID: 17110824
    [Abstract] [Full Text] [Related]

  • 8. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
    Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL, Moore RJ, Renard D, Brady KT, Trzepacz PT, Schuh LM, Ahrbecker LM, Levine LR, Atomoxetine ADHD/SUD Study Group.
    Drug Alcohol Depend; 2008 Jul 01; 96(1-2):145-54. PubMed ID: 18403134
    [Abstract] [Full Text] [Related]

  • 9. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA, Pliszka SR.
    Pharmacotherapy; 2009 Jun 01; 29(6):656-79. PubMed ID: 19476419
    [Abstract] [Full Text] [Related]

  • 10. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE, Newcorn JH, Kratochvil CJ, Gao H, Thomason CK, Rogers AK, Feldman PD, Levine LR.
    J Pediatr; 2006 Jul 01; 149(1):112-9. PubMed ID: 16860138
    [Abstract] [Full Text] [Related]

  • 11. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome.
    Spencer TJ, Sallee FR, Gilbert DL, Dunn DW, McCracken JT, Coffey BJ, Budman CL, Ricardi RK, Leonard HL, Allen AJ, Milton DR, Feldman PD, Kelsey DK, Geller DA, Linder SL, Lewis DW, Winner PK, Kurlan RM, Mintz M.
    J Atten Disord; 2008 Jan 01; 11(4):470-81. PubMed ID: 17934184
    [Abstract] [Full Text] [Related]

  • 12. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
    Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, Saidi A.
    Ann Pharmacother; 2008 Jan 01; 42(1):24-31. PubMed ID: 18042808
    [Abstract] [Full Text] [Related]

  • 13. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, Williams DW, Moore RJ, Levine L, Atomoxetine ADHD/ODD Study Group.
    Pediatrics; 2008 Feb 01; 121(2):e314-20. PubMed ID: 18245404
    [Abstract] [Full Text] [Related]

  • 14. Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning.
    Brown RT, Perwien A, Faries DE, Kratochvil CJ, Vaughan BS.
    Clin Pediatr (Phila); 2006 Nov 01; 45(9):819-27. PubMed ID: 17041169
    [Abstract] [Full Text] [Related]

  • 15. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year.
    Buitelaar JK, Michelson D, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, Faries DE, Zhang S, Biederman J.
    Biol Psychiatry; 2007 Mar 01; 61(5):694-9. PubMed ID: 16893523
    [Abstract] [Full Text] [Related]

  • 16. Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective.
    Lachaine J, Beauchemin C, Sasane R, Hodgkins PS.
    Postgrad Med; 2012 May 01; 124(3):139-48. PubMed ID: 22691908
    [Abstract] [Full Text] [Related]

  • 17. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations.
    Molife C, Bernauer MJ, Farr AM, Haynes VS, Kelsey D.
    Postgrad Med; 2012 Sep 01; 124(5):7-22. PubMed ID: 23095422
    [Abstract] [Full Text] [Related]

  • 18. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment.
    Wernicke JF, Adler L, Spencer T, West SA, Allen AJ, Heiligenstein J, Milton D, Ruff D, Brown WJ, Kelsey D, Michelson D.
    J Clin Psychopharmacol; 2004 Feb 01; 24(1):30-5. PubMed ID: 14709944
    [Abstract] [Full Text] [Related]

  • 19. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.
    Wernicke JF, Kratochvil CJ.
    J Clin Psychiatry; 2002 Feb 01; 63 Suppl 12():50-5. PubMed ID: 12562062
    [Abstract] [Full Text] [Related]

  • 20. Comparison of clonidine response in the treatment of attention-deficit hyperactivity disorder with and without comorbid tic disorders.
    Steingard R, Biederman J, Spencer T, Wilens T, Gonzalez A.
    J Am Acad Child Adolesc Psychiatry; 1993 Mar 01; 32(2):350-3. PubMed ID: 8444764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.